BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 10705304)

  • 1. Hepatocyte growth factor plasma levels after myocardial infarction are not affected by recombinant tissue-type plasminogen-activator therapy.
    Molnar C; Buratti T; Wiedermann CJ; Tilg H
    Eur Cytokine Netw; 2000 Mar; 11(1):87-90. PubMed ID: 10705304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased circulating hepatocyte growth factor in the early stage of acute myocardial infarction.
    Matsumori A; Furukawa Y; Hashimoto T; Ono K; Shioi T; Okada M; Iwasaki A; Nishio R; Sasayama S
    Biochem Biophys Res Commun; 1996 Apr; 221(2):391-5. PubMed ID: 8619866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Changes of serum hepatocyte growth factor in coronary artery disease].
    Suzuki H; Murakami M; Kondo T; Shibata M; Ezumi H; Okabayashi H; Yorozuya M; Makishima N; Hamazaki Y; Nakatani M; Namiki A; Katagiri T
    J Cardiol; 2000 May; 35(5):319-24. PubMed ID: 10834175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum levels of endostatin, vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in patients with acute myocardial infarction undergoing early reperfusion therapy.
    Seko Y; Fukuda S; Nagai R
    Clin Sci (Lond); 2004 May; 106(5):439-42. PubMed ID: 14965340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non neutralizing antibodies to tissue type plasminogen activator in the serum of acute myocardial infarction patients treated with the recombinant protein.
    Cugno M; Cicardi M; Colucci M; Bisiani G; Merlini PA; Spinola A; Paonessa R; Agostoni A
    Thromb Haemost; 1996 Aug; 76(2):234-8. PubMed ID: 8865537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Significance of hepatocyte growth factor measurement in patients with acute myocardial infarction].
    Sato T; Yoshinouchi T; Sugimoto T; Sakamoto T; Fujieda H; Sato H; Murao S; Kobayashi H; Ohe T
    J Cardiol; 1998 Aug; 32(2):77-82. PubMed ID: 9752615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Von Willebrand factor, plasminogen activator inhibitor-1 and C-reactive protein are markers of thrombolytic efficacy in acute myocardial infarction.
    Andreotti F; Hackett DR; Haider AW; Roncaglioni MC; Davies GJ; Beacham JL; Kluft C; Maseri A
    Thromb Haemost; 1992 Dec; 68(6):678-82. PubMed ID: 1287882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HGF, MET, and matrix-related proteases in hepatocellular carcinoma, fibrolamellar variant, cirrhotic and normal liver.
    Schoedel KE; Tyner VZ; Kim TH; Michalopoulos GK; Mars WM
    Mod Pathol; 2003 Jan; 16(1):14-21. PubMed ID: 12527708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute stroke management in the elderly.
    Zeevi N; Chhabra J; Silverman IE; Lee NS; McCullough LD
    Cerebrovasc Dis; 2007; 23(4):304-8. PubMed ID: 17199089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial effects of diltiazem during myocardial reperfusion: a randomized trial in acute myocardial infarction.
    Pizzetti G; Mailhac A; Li Volsi L; Di Marco F; Lu C; Margonato A; Chierchia SL
    Ital Heart J; 2001 Oct; 2(10):757-65. PubMed ID: 11721720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alteplase treatment affects circulating matrix metalloproteinase concentrations in patients with ST segment elevation acute myocardial infarction.
    Tziakas DN; Chalikias GK; Hatzinikolaou EI; Stakos DA; Tentes IK; Kortsaris A; Hatseras DI; Kaski JC
    Thromb Res; 2006; 118(2):221-7. PubMed ID: 16126256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of retarded liver regeneration in plasminogen activator-deficient mice: impaired activation of hepatocyte growth factor after Fas-mediated massive hepatic apoptosis.
    Shimizu M; Hara A; Okuno M; Matsuno H; Okada K; Ueshima S; Matsuo O; Niwa M; Akita K; Yamada Y; Yoshimi N; Uematsu T; Kojima S; Friedman SL; Moriwaki H; Mori H
    Hepatology; 2001 Mar; 33(3):569-76. PubMed ID: 11230736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of thrombolysis with alteplase (50 mg) plus tirofiban versus alteplase (100 mg) alone in acute myocardial infarction: preliminary findings.
    Sarullo FM; Pasquale PD; D'Alfonso G; Amerigo L; Cannizzaro S; Castello A
    Ital Heart J; 2001 Aug; 2(8):605-11. PubMed ID: 11577835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Procoagulant properties of intravenous staphylokinase versus tissue-type plasminogen activator.
    Okada K; Lijnen HR; Moreau H; Vanderschueren S; Collen D
    Thromb Haemost; 1996 Dec; 76(6):857-9. PubMed ID: 8972000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Impact of intravenous thrombolysis prior to percutaneous coronary intervention in reperfusion therapy for acute myocardial infarction].
    Uto K; Ota Y; Mizuno M; Nakamura A; Nakajima R; Endoh Y; Kasanuki H
    J Cardiol; 2002 Dec; 40(6):241-8. PubMed ID: 12528645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of the contact system and inflammation after thrombolytic therapy in patients with acute myocardial infarction.
    Merlini PA; Cugno M; Rossi ML; Agricola P; Repetto A; Fetiveau R; Diotallevi P; Canosi U; Mannucci PM; Ardissino D
    Am J Cardiol; 2004 Apr; 93(7):822-5. PubMed ID: 15050482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of cardiac output on peak t-PA plasma levels in patients receiving thrombolytic therapy with recombinant tissue-type plasminogen activator--correlation with patency rate.
    Huber K; Beckmann R; Probst P; Rauscha F; Kaindl F; Binder BR
    Thromb Haemost; 1993 Jan; 69(1):45-9. PubMed ID: 8446938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocyte growth factor and vascular endothelial growth factor in ischaemic heart disease.
    Suzuki H; Murakami M; Shoji M; Iso Y; Kondo T; Shibata M; Ezumi H; Hamazaki Y; Koba S; Katagiri T
    Coron Artery Dis; 2003 Jun; 14(4):301-7. PubMed ID: 12826929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of recombinant tissue-type plasminogen activator thrombolysis and primary coronary stenting after acute myocardial infarction.
    Chen B; Wang W; Zhao H; Hu D; Xu C; Zhao M; Lu M; Liu J; Wu C
    Chin Med J (Engl); 2003 Jan; 116(1):142-4. PubMed ID: 12667408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The safety and efficacy of systemic salvage thrombolysis in acute myocardial infarct].
    Sarullo FM; Schicchi R; SchirĂ² M; Americo L; Bonnì G; Faraone N; Di Pasquale P; Castello A; Mauri F
    Ital Heart J Suppl; 2000 Jan; 1(1):81-7. PubMed ID: 10832123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.